Journal article · 2025 · Open access
The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt
The Journal of Clinical Psychiatry, 86(3) · Published 25 August 2025 · DOI 10.4088/jcp.25f16038
In brief
“The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt” is a 2025 journal article by Chittaranjan Andrade, published in The Journal of Clinical Psychiatry. OpenAlex counts 1 citations as of 20 November 2026. It is open access: the full text is free to read at The Journal of Clinical Psychiatry.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.43
- References
- 42
- Authors
- 1
Abstract
Schizophrenia is a major mental illness with a median lifetime prevalence, across studies, of 0.5%. Across definitions of treatment resistance, about 37% of schizophrenia patients do not respond to treatment, and about 24% are treatment resistant from the first-episode, itself. Treatment resistance is addressed by trialing different antipsychotics and with antipsychotic augmentation strategies; what augmenting agent is used depends on what the target symptoms are. A landmark study in 1988 demonstrated the efficacy of clozapine in treatment resistant schizophrenia (TRS). Confirmatory studies and meta-analyses followed, establishing clozapine as the drug of choice for TRS in schizophrenia treatment guidelines across the world. Between 2016 and 2025, 2 network meta analyses (NMAs) and 1 individual participant data meta-analysis (IPD-MA) examined randomized controlled trials (RCTs) of clozapine vs other antipsychotics in TRS. The NMAs found that clozapine was superior to first-generation antipsychotics; however, clozapine did not head rankings for overall symptoms, positive symptoms, or negative symptoms, and, in pairwise analyses, there was little difference between clozapine and olanzapine and clozapine and risperidone for overall symptoms, positive symptoms, and negative symptoms. The IPD-MA found that clozapine was no better than comparator second-generation antipsychotics, considered singly or together, for overall symptoms, positive symptoms, and negative symptoms, in the short term, intermediate term, and long term. These findings fly in the face of clinical experience and treatment guideline recommendations. Among possible explanations, notable was that clozapine was significantly superior to comparator drugs when disregarding RCTs sponsored by the manufacturer of olanzapine. Clozapine is associated with many inconveniencing, distressing, and serious adverse effects that may be rare or common. Given the findings that olanzapine and risperidone may be as good as clozapine in TRS, it may be worth trialing these drugs before clozapine in patients with TRS. These and related issues, including nuances, are discussed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Andrade, C. (2025). The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt. The Journal of Clinical Psychiatry, 86(3). https://doi.org/10.4088/jcp.25f16038
MLA 9
Andrade, Chittaranjan. “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt.” The Journal of Clinical Psychiatry, vol. 86, no. 3, 2025. https://doi.org/10.4088/jcp.25f16038.
Chicago
Andrade, Chittaranjan. 2025. “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt.” The Journal of Clinical Psychiatry 86 (3). https://doi.org/10.4088/jcp.25f16038.
Harvard
Andrade, C. (2025) ‘The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt’, The Journal of Clinical Psychiatry, 86(3). doi:10.4088/jcp.25f16038.
IEEE
C. Andrade, “The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt,” The Journal of Clinical Psychiatry, vol. 86, no. 3, 2025, doi: 10.4088/jcp.25f16038.
BibTeX
@article{andrade2025superiority,
title = {{The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt}},
author = {Andrade, Chittaranjan},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
volume = {86},
number = {3},
doi = {10.4088/jcp.25f16038},
url = {https://doi.org/10.4088/jcp.25f16038}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- clozapine
- treatment-resistant schizophrenia
- atypical antipsychotics
- olanzapine
- risperidone
- antipsychotic augmentation
- network meta-analysis
- individual patient data meta-analysis
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Andrade, C. (2025). The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt. The Journal of Clinical Psychiatry, 86(3). https://doi.org/10.4088/jcp.25f16038
How many times has this paper been cited?
1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Journal of Clinical Psychiatry: sign in and open the PDF from this page.
Who wrote this paper?
Chittaranjan Andrade.
What is the DOI of this paper?
10.4088/jcp.25f16038, permanently at https://doi.org/10.4088/jcp.25f16038. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.